Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SB-01
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase III
Sponsor : Spine BioPharma
Deal Size : $155.0 million
Deal Type : Agreement
Spine BioPharma Signs with Ensol BioSciences to Expand Indications for SB-01 Injection
Details : Spine BioPharma acquired the right to develop and commercialize SB-01, excluding Korea. It is being evaluated for the treatment of pain-related disability, associated with Degenerative Disc Disease.
Brand Name : SB-01
Molecule Type : Peptide
Upfront Cash : Undisclosed
July 10, 2024
Lead Product(s) : SB-01
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase III
Sponsor : Spine BioPharma
Deal Size : $155.0 million
Deal Type : Agreement
LOOKING FOR A SUPPLIER?